NO329652B1 - Anvendelse av aktivert trekull til fremstilling av et middel for inhibering av peritonealdialyseassosierte komplikasjoner, samt fremgangsmate for fremstilling av peritonealdialysevaeske med redusert karbonylforbindelsesinnhold. - Google Patents
Anvendelse av aktivert trekull til fremstilling av et middel for inhibering av peritonealdialyseassosierte komplikasjoner, samt fremgangsmate for fremstilling av peritonealdialysevaeske med redusert karbonylforbindelsesinnhold. Download PDFInfo
- Publication number
- NO329652B1 NO329652B1 NO20010931A NO20010931A NO329652B1 NO 329652 B1 NO329652 B1 NO 329652B1 NO 20010931 A NO20010931 A NO 20010931A NO 20010931 A NO20010931 A NO 20010931A NO 329652 B1 NO329652 B1 NO 329652B1
- Authority
- NO
- Norway
- Prior art keywords
- peritoneal dialysis
- dialysis fluid
- carbonyl
- carbonyl compound
- peritoneal
- Prior art date
Links
- 150000001728 carbonyl compounds Chemical class 0.000 title claims abstract description 226
- 239000003330 peritoneal dialysis fluid Substances 0.000 title claims abstract description 133
- 238000000502 dialysis Methods 0.000 title claims abstract description 88
- 239000003795 chemical substances by application Substances 0.000 title claims abstract description 85
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 title claims description 74
- 230000002401 inhibitory effect Effects 0.000 title claims description 12
- 230000002829 reductive effect Effects 0.000 title claims description 10
- 238000002360 preparation method Methods 0.000 title claims description 6
- 238000000034 method Methods 0.000 title description 40
- AIJULSRZWUXGPQ-UHFFFAOYSA-N Methylglyoxal Chemical compound CC(=O)C=O AIJULSRZWUXGPQ-UHFFFAOYSA-N 0.000 claims description 76
- 239000000126 substance Substances 0.000 claims description 27
- 238000006243 chemical reaction Methods 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 16
- 235000000346 sugar Nutrition 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 abstract description 38
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 38
- 210000000683 abdominal cavity Anatomy 0.000 abstract description 26
- 210000004369 blood Anatomy 0.000 abstract description 21
- 239000008280 blood Substances 0.000 abstract description 21
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 abstract description 18
- 238000003860 storage Methods 0.000 abstract description 17
- 239000012530 fluid Substances 0.000 abstract description 11
- 239000002516 radical scavenger Substances 0.000 abstract description 11
- 230000009145 protein modification Effects 0.000 abstract description 5
- 238000007912 intraperitoneal administration Methods 0.000 abstract description 4
- 208000012896 Peritoneal disease Diseases 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 68
- 239000008103 glucose Substances 0.000 description 68
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 41
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 41
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 41
- 230000015572 biosynthetic process Effects 0.000 description 35
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 32
- 108090000623 proteins and genes Proteins 0.000 description 27
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 26
- 235000018102 proteins Nutrition 0.000 description 26
- 102000004169 proteins and genes Human genes 0.000 description 26
- 238000002474 experimental method Methods 0.000 description 25
- 230000000694 effects Effects 0.000 description 23
- 108020004999 messenger RNA Proteins 0.000 description 22
- 210000004303 peritoneum Anatomy 0.000 description 22
- 239000000203 mixture Substances 0.000 description 21
- 239000011324 bead Substances 0.000 description 18
- -1 polytersulfone Polymers 0.000 description 18
- 230000035882 stress Effects 0.000 description 18
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 17
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 16
- 229940015043 glyoxal Drugs 0.000 description 16
- 239000007857 degradation product Substances 0.000 description 15
- 239000000385 dialysis solution Substances 0.000 description 15
- 210000005033 mesothelial cell Anatomy 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 229920000642 polymer Polymers 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- AYEKKSTZQYEZPU-RYUDHWBXSA-N pentosidine Chemical compound OC(=O)[C@@H](N)CCCCN1C=CC=C2N=C(NCCC[C@H](N)C(O)=O)N=C12 AYEKKSTZQYEZPU-RYUDHWBXSA-N 0.000 description 13
- ZGCHLOWZNKRZSN-NTSWFWBYSA-N 3-deoxyglucosone Chemical compound OC[C@@H](O)[C@@H](O)CC(=O)C=O ZGCHLOWZNKRZSN-NTSWFWBYSA-N 0.000 description 12
- UHPMJDGOAZMIID-UHFFFAOYSA-N 3-deoxyglucosone Natural products OCC1OC(O)C(=O)CC1O UHPMJDGOAZMIID-UHFFFAOYSA-N 0.000 description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 12
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 12
- 210000003734 kidney Anatomy 0.000 description 12
- 239000012488 sample solution Substances 0.000 description 12
- HORQAOAYAYGIBM-UHFFFAOYSA-N 2,4-dinitrophenylhydrazine Chemical compound NNC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O HORQAOAYAYGIBM-UHFFFAOYSA-N 0.000 description 11
- 210000003200 peritoneal cavity Anatomy 0.000 description 11
- RRUYWEMUWIRRNB-LURJTMIESA-N (2s)-6-amino-2-[carboxy(methyl)amino]hexanoic acid Chemical compound OC(=O)N(C)[C@H](C(O)=O)CCCCN RRUYWEMUWIRRNB-LURJTMIESA-N 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- NOEGNKMFWQHSLB-UHFFFAOYSA-N 5-hydroxymethylfurfural Chemical compound OCC1=CC=C(C=O)O1 NOEGNKMFWQHSLB-UHFFFAOYSA-N 0.000 description 9
- 238000011088 calibration curve Methods 0.000 description 9
- 230000015556 catabolic process Effects 0.000 description 9
- RJGBSYZFOCAGQY-UHFFFAOYSA-N hydroxymethylfurfural Natural products COC1=CC=C(C=O)O1 RJGBSYZFOCAGQY-UHFFFAOYSA-N 0.000 description 9
- 230000007935 neutral effect Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 150000001720 carbohydrates Chemical class 0.000 description 8
- 238000006731 degradation reaction Methods 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 238000009825 accumulation Methods 0.000 description 7
- 230000002378 acidificating effect Effects 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000011148 porous material Substances 0.000 description 7
- 230000003321 amplification Effects 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- 238000012744 immunostaining Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 229940118019 malondialdehyde Drugs 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 230000002792 vascular Effects 0.000 description 6
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 5
- 208000001647 Renal Insufficiency Diseases 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 201000006370 kidney failure Diseases 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 4
- UBDZFAGVPPMTIT-UHFFFAOYSA-N 2-aminoguanidine;hydron;chloride Chemical compound [Cl-].NC(N)=N[NH3+] UBDZFAGVPPMTIT-UHFFFAOYSA-N 0.000 description 4
- JOOXCMJARBKPKM-UHFFFAOYSA-N 4-oxopentanoic acid Chemical compound CC(=O)CCC(O)=O JOOXCMJARBKPKM-UHFFFAOYSA-N 0.000 description 4
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 238000009739 binding Methods 0.000 description 4
- 239000006172 buffering agent Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 229920002457 flexible plastic Polymers 0.000 description 4
- 230000036252 glycation Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 229920002521 macromolecule Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000002250 absorbent Substances 0.000 description 3
- 230000002745 absorbent Effects 0.000 description 3
- 238000003149 assay kit Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 125000004989 dicarbonyl group Chemical group 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229960004329 metformin hydrochloride Drugs 0.000 description 3
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 3
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin hydrochloride Natural products CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000006711 vascular endothelial growth factor production Effects 0.000 description 3
- ISNKSXRJJVWFIL-UHFFFAOYSA-N (sulfonylamino)amine Chemical group NN=S(=O)=O ISNKSXRJJVWFIL-UHFFFAOYSA-N 0.000 description 2
- JVJFIQYAHPMBBX-UHFFFAOYSA-N 4-hydroxynonenal Chemical compound CCCCCC(O)C=CC=O JVJFIQYAHPMBBX-UHFFFAOYSA-N 0.000 description 2
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 206010071945 Dialysis related complications Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 208000016463 Wild type ABeta2M amyloidosis Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 238000001631 haemodialysis Methods 0.000 description 2
- 230000000322 hemodialysis Effects 0.000 description 2
- 150000007857 hydrazones Chemical class 0.000 description 2
- 230000003100 immobilizing effect Effects 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229910017053 inorganic salt Inorganic materials 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940040102 levulinic acid Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000000051 modifying effect Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 206010034674 peritonitis Diseases 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 229920002492 poly(sulfone) Polymers 0.000 description 2
- 229920002239 polyacrylonitrile Polymers 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000002683 reaction inhibitor Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- SPFMQWBKVUQXJV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;hydrate Chemical compound O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O SPFMQWBKVUQXJV-BTVCFUMJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- STRVVRPNBAHXRJ-UHFFFAOYSA-N 2-hydroxynon-2-enal Chemical compound CCCCCCC=C(O)C=O STRVVRPNBAHXRJ-UHFFFAOYSA-N 0.000 description 1
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 1
- ZZFSVZSLTOWVQU-UHFFFAOYSA-N 3-silyloxyperoxypropan-1-amine Chemical compound NCCCOOO[SiH3] ZZFSVZSLTOWVQU-UHFFFAOYSA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010075 Coma hepatic Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 1
- SBJKKFFYIZUCET-UHFFFAOYSA-N Dehydroascorbic acid Natural products OCC(O)C1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 238000005773 Enders reaction Methods 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010034665 Peritoneal fibrosis Diseases 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 101000885869 Rattus norvegicus Glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 101000808006 Rattus norvegicus Vascular endothelial growth factor A Proteins 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 238000012084 abdominal surgery Methods 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 235000020960 dehydroascorbic acid Nutrition 0.000 description 1
- 239000011615 dehydroascorbic acid Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000002637 fluid replacement therapy Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 108091005995 glycated hemoglobin Proteins 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 201000001059 hepatic coma Diseases 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 102000058223 human VEGFA Human genes 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 210000004924 lung microvascular endothelial cell Anatomy 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 210000003245 peritoneal mesothelial cell Anatomy 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000110 poly(aryl ether sulfone) Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 229920001470 polyketone Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920005990 polystyrene resin Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000007065 protein hydrolysis Effects 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 125000005372 silanol group Chemical group 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229920005573 silicon-containing polymer Polymers 0.000 description 1
- 229920002050 silicone resin Polymers 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- KKEYFWRCBNTPAC-UHFFFAOYSA-L terephthalate(2-) Chemical compound [O-]C(=O)C1=CC=C(C([O-])=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-L 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
- A61M1/287—Dialysates therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- External Artificial Organs (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP23710898 | 1998-08-24 | ||
| JP15539399 | 1999-06-02 | ||
| PCT/JP1999/004521 WO2000010606A1 (fr) | 1998-08-24 | 1999-08-23 | Medicaments de sedation de l'agression du carbonyle et des dialysats peritoneaux |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20010931D0 NO20010931D0 (no) | 2001-02-23 |
| NO20010931L NO20010931L (no) | 2001-04-23 |
| NO329652B1 true NO329652B1 (no) | 2010-11-22 |
Family
ID=26483408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20010931A NO329652B1 (no) | 1998-08-24 | 2001-02-23 | Anvendelse av aktivert trekull til fremstilling av et middel for inhibering av peritonealdialyseassosierte komplikasjoner, samt fremgangsmate for fremstilling av peritonealdialysevaeske med redusert karbonylforbindelsesinnhold. |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US6919326B1 (ja) |
| EP (2) | EP2070535B1 (ja) |
| JP (1) | JP3811008B2 (ja) |
| KR (1) | KR100478181B1 (ja) |
| CN (1) | CN1150034C (ja) |
| AU (1) | AU756847B2 (ja) |
| CA (2) | CA2339879C (ja) |
| NO (1) | NO329652B1 (ja) |
| WO (1) | WO2000010606A1 (ja) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6436969B1 (en) | 1995-09-12 | 2002-08-20 | Kansas University Medical Center Research Institute Inc. | Dialysis solutions and methods |
| WO2000010606A1 (fr) | 1998-08-24 | 2000-03-02 | Kurokawa, Kiyoshi | Medicaments de sedation de l'agression du carbonyle et des dialysats peritoneaux |
| WO2000059493A2 (en) * | 1999-04-06 | 2000-10-12 | Kansas University Medical Center | Improved dialysis solutions and methods |
| AU778462C (en) * | 1999-05-12 | 2006-02-02 | Kurokawa, Kiyoshi | Blood carbonyl compound-trapping agent |
| AU780855B2 (en) * | 1999-10-06 | 2005-04-21 | Kurokawa, Kiyoshi | Carbonyl stress-decreasing agent |
| EP1240902B1 (en) | 1999-12-20 | 2013-02-13 | Kurokawa, Kiyoshi | Carbonyl stress-ameliorating agents |
| JP4882054B2 (ja) | 2000-09-13 | 2012-02-22 | 独立行政法人科学技術振興機構 | 腹膜透析液およびその調製法 |
| WO2002047677A1 (fr) * | 2000-12-12 | 2002-06-20 | Tokai University Educational System | Agents d'amelioration du stress du a un groupement carbonyle |
| JP2003019198A (ja) * | 2001-07-06 | 2003-01-21 | Jms Co Ltd | 腹膜透析液 |
| CA2506704C (en) * | 2002-11-21 | 2013-06-25 | Kowa Co., Ltd. | Peritoneal dialysis method |
| US8038639B2 (en) | 2004-11-04 | 2011-10-18 | Baxter International Inc. | Medical fluid system with flexible sheeting disposable unit |
| US8029454B2 (en) | 2003-11-05 | 2011-10-04 | Baxter International Inc. | High convection home hemodialysis/hemofiltration and sorbent system |
| AU2004294435B2 (en) | 2003-12-05 | 2010-07-08 | Kiyoshi Kurokawa | Inhibitor of protein modification products formation |
| US7384558B2 (en) | 2004-07-26 | 2008-06-10 | Baxter International Inc. | Compositions capable of inhibiting reactive oxygen and carbonyl species |
| WO2006115067A1 (ja) | 2005-04-20 | 2006-11-02 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | 腹膜透析液 |
| US20090030047A1 (en) * | 2005-05-24 | 2009-01-29 | Tokai University Educational System | Peritoneum protecting agent |
| US8543420B2 (en) * | 2007-09-19 | 2013-09-24 | Fresenius Medical Care Holdings, Inc. | Patient-specific content delivery methods and systems |
| WO2007097922A2 (en) * | 2006-02-07 | 2007-08-30 | The Regents Of Northwestern University | Receptor-based blood detoxification system |
| JP4004523B1 (ja) * | 2006-04-21 | 2007-11-07 | 株式会社日本トリム | 透析液調製用水およびそれを用いた透析液、透析液の製造方法ならびに透析装置 |
| US8777891B2 (en) * | 2006-07-27 | 2014-07-15 | Fresenius Medical Care Holdings, Inc. | Apparatus and methods for early stage peritonitis detection and for in vivo testing of bodily fluid |
| US8801652B2 (en) * | 2006-07-27 | 2014-08-12 | Fresenius Medical Care Holding, Inc. | Early stage peritonitis detection apparatus and methods |
| US8728023B2 (en) * | 2006-07-27 | 2014-05-20 | Fresenius Medical Care Holdings, Inc. | Apparatus and methods for early stage peritonitis detection including self-cleaning effluent chamber |
| US8114276B2 (en) | 2007-10-24 | 2012-02-14 | Baxter International Inc. | Personal hemodialysis system |
| WO2009094034A1 (en) * | 2008-01-25 | 2009-07-30 | Fresenius Medical Care Holdings, Inc. | Apparatus and methods for early stage peritonitis detection including self-cleaning effluent chamber |
| WO2009113578A1 (ja) | 2008-03-13 | 2009-09-17 | 味の素株式会社 | カルボニル化合物除去材 |
| US8882700B2 (en) | 2008-05-02 | 2014-11-11 | Baxter International Inc. | Smart patient transfer set for peritoneal dialysis |
| US9348975B2 (en) | 2008-05-02 | 2016-05-24 | Baxter International Inc. | Optimizing therapy outcomes for peritoneal dialysis |
| US8057679B2 (en) | 2008-07-09 | 2011-11-15 | Baxter International Inc. | Dialysis system having trending and alert generation |
| US8698741B1 (en) | 2009-01-16 | 2014-04-15 | Fresenius Medical Care Holdings, Inc. | Methods and apparatus for medical device cursor control and touchpad-based navigation |
| EP2391404B1 (en) | 2009-01-30 | 2013-01-16 | Baxter International Inc. | Transfer sets for therapy optimization |
| FR2945043B1 (fr) * | 2009-04-30 | 2019-07-26 | Roquette Freres | Procede de purification de polymeres de glucose destines aux solutions de dialyse peritoneale |
| US8282829B2 (en) | 2009-05-20 | 2012-10-09 | Baxter International Inc. | System and method for automated data collection of twenty-four hour ultrafiltration and other patient parameters using wired or wireless technology |
| US9020827B2 (en) * | 2009-10-16 | 2015-04-28 | Baxter International Inc. | Peritoneal dialysis optimized using a patient hand-held scanning device |
| US8632485B2 (en) * | 2009-11-05 | 2014-01-21 | Fresenius Medical Care Holdings, Inc. | Patient treatment and monitoring systems and methods |
| CN103052389A (zh) | 2010-07-23 | 2013-04-17 | 学校法人东海大学 | 腹膜透析患者用口服药物组合物及其用法 |
| CA2839460C (en) | 2011-06-24 | 2017-08-22 | Richard W.C. LO | Multi-container systems and uses thereof |
| FR3055898B1 (fr) * | 2016-09-15 | 2018-11-02 | Roquette Freres | Nouveaux polymeres de glucose pour dialyse peritoneale |
| GR20160100569A (el) * | 2016-11-04 | 2018-08-29 | Πανεπιστημιο Πατρων | Μεθοδος για τη φθορισμομετρικη ανιχνευση και/ή ποροστικοποιηση των πρωτεϊνικων καρβονυλομαδων |
| CN109364098B (zh) * | 2018-11-30 | 2021-09-21 | 威高泰尔茂(威海)医疗制品有限公司 | 中性pH值腹膜透析液及其制备工艺 |
| CN110327886B (zh) * | 2019-06-12 | 2021-12-07 | 太原理工大学 | 一种沸石咪唑酯骨架材料及其制备方法和应用 |
Family Cites Families (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3284531A (en) | 1965-07-06 | 1966-11-08 | Dow Chemical Co | Removing carbonyl sulfide with an anhydrous, basic, anion resin |
| US3793187A (en) | 1971-08-19 | 1974-02-19 | Erdoelchemie Gmbh | Process for removing carbonyl compounds from hydrocarbons |
| US4131544A (en) | 1976-08-03 | 1978-12-26 | Nasik Elahi | Macroencapsulated sorbent element and process for using the same |
| US4171283A (en) | 1976-08-04 | 1979-10-16 | Kuraray Co., Ltd. | Hemoperfusion adsorbents |
| EP0064393A3 (en) | 1981-05-04 | 1982-12-29 | Purdue Research Foundation | Sorbent mixture for use in hemodialysis |
| EP0089135A1 (en) | 1982-03-17 | 1983-09-21 | The Curators Of The University Of Missouri | Peritoneal dialysis solution containing sorbents |
| US4665192A (en) | 1984-03-19 | 1987-05-12 | The Rockefeller University | 2-(2-furoyl)-4(5)-2(furanyl)-1H-imidazole |
| US5114943A (en) | 1984-03-19 | 1992-05-19 | The Rockefeller University | Amino-substituted pyrimidines, derivatives and methods of use therefor |
| US4983604A (en) | 1987-11-13 | 1991-01-08 | The Rockefeller University | Inhibitors of nonenzymatic cross-linking |
| US4758583A (en) | 1984-03-19 | 1988-07-19 | The Rockefeller University | Method and agents for inhibiting protein aging |
| US5852009A (en) | 1984-03-19 | 1998-12-22 | The Rockefeller University | Compositions, including pharmaceutical compositions, for inhibiting the advanced glycosylation of proteins, and therapeutic methods based thereon |
| US5272176A (en) | 1984-03-19 | 1993-12-21 | The Rockefeller University | Advanced glycation inhibitors containing amino-benzoic acids and derivatives, and methods of use |
| US5334617A (en) | 1984-03-19 | 1994-08-02 | The Rockefeller University | Amino acids useful as inhibitors of the advanced glycosylation of proteins |
| JPS62249909A (ja) | 1986-04-21 | 1987-10-30 | Lion Corp | コラ−ゲンの架橋反応抑制剤 |
| JPS62249908A (ja) | 1986-04-21 | 1987-10-30 | Lion Corp | コラ−ゲンの架橋反応抑制剤 |
| JPS62249709A (ja) | 1986-04-24 | 1987-10-30 | 松下電工株式会社 | 木材の染色方法 |
| JPH0626563B2 (ja) * | 1986-07-10 | 1994-04-13 | 株式会社新素材総合研究所 | 医療用容器及びその製造方法 |
| US5026341A (en) | 1987-05-22 | 1991-06-25 | Robert Giebeler | Low speed disengageable damper |
| JPS6456614A (en) | 1987-08-27 | 1989-03-03 | Ono Pharmaceutical Co | Maillard reaction inhibitor |
| JP2548223B2 (ja) | 1987-08-27 | 1996-10-30 | 第一製薬株式会社 | 腎臓疾患治療剤 |
| JPS6483059A (en) | 1987-09-25 | 1989-03-28 | Ono Pharmaceutical Co | Guanidine derivative, its production and maillard reaction inhibitor containing said derivative as active component |
| JPS6456615U (ja) | 1987-10-03 | 1989-04-10 | ||
| JPH0534496Y2 (ja) | 1987-10-03 | 1993-09-01 | ||
| JPH02753A (ja) | 1987-12-24 | 1990-01-05 | Ono Pharmaceut Co Ltd | カルバゾイル誘導体、それらの製造方法およびそれらを有効成分として含有するメイラード反応阻害剤 |
| EP0323590A3 (en) | 1987-12-24 | 1990-05-02 | Ono Pharmaceutical Co., Ltd. | Carbazoyl derivatives |
| JPH02765A (ja) | 1988-01-16 | 1990-01-05 | Ono Pharmaceut Co Ltd | アミノグアニジン誘導体およびそれらを有効成分として含有するメイラード反応阻害剤 |
| EP0339496A3 (en) | 1988-04-26 | 1991-05-08 | Ono Pharmaceutical Co., Ltd. | Aminoguanidine derivatives |
| JP2652556B2 (ja) | 1988-08-29 | 1997-09-10 | 株式会社浅井ゲルマニウム研究所 | 有機ゲルマニウム化合物及びその製造方法 |
| JP2817219B2 (ja) | 1988-09-08 | 1998-10-30 | 武田薬品工業株式会社 | カルバジン酸誘導体、その製造法及び製剤 |
| JPH04502611A (ja) | 1988-09-28 | 1992-05-14 | ペプタイド・テクノロジー・リミテッド | コラーゲンの架橋の抑制用化合物および抑制方法 |
| WO1990006102A1 (en) | 1988-09-28 | 1990-06-14 | Peptide Technology Limited | Compound and method for the retardation of collagen cross-linking |
| CA2011899A1 (en) | 1989-03-13 | 1990-09-13 | Masaaki Toda | Benzopyran derivatives |
| US5032281A (en) * | 1989-08-09 | 1991-07-16 | Daicel Chemical Industries, Ltd. | Separating membrane and separation method |
| JPH03148220A (ja) | 1989-11-02 | 1991-06-25 | Otsuka Pharmaceut Co Ltd | 糖化蛋白分解剤 |
| JPH03161441A (ja) | 1989-11-20 | 1991-07-11 | Senjiyu Seiyaku Kk | メイラード反応阻害剤 |
| WO1991012799A1 (en) | 1990-02-28 | 1991-09-05 | The Upjohn Company | Use of 3-guanidinopropionic acid in the treatment and prevention of metabolic disorders |
| JPH03240725A (ja) | 1990-02-15 | 1991-10-28 | Senjiyu Seiyaku Kk | メイラード反応阻害剤 |
| DE69113938T2 (de) | 1990-02-19 | 1996-04-11 | Senju Pharma Co | Zusammensetzungen von Maillard-Reaktion inhibitoren. |
| JPH03261772A (ja) | 1990-03-09 | 1991-11-21 | Suntory Ltd | チアゾリジン系化合物およびこれを含有するグリケーション阻害剤 |
| JPH05310565A (ja) | 1990-04-03 | 1993-11-22 | Univ Rockefeller | 蛋白質の高度グリコシル化抑制組成物及び抑制方法 |
| JPH049375A (ja) | 1990-04-25 | 1992-01-14 | Takeda Chem Ind Ltd | チオ尿素誘導体及びａｇｅ生成阻害剤 |
| JPH059114A (ja) | 1990-08-29 | 1993-01-19 | Takeda Chem Ind Ltd | 糖尿病性合併症の予防・治療剤 |
| JP2512628B2 (ja) * | 1990-11-21 | 1996-07-03 | 株式会社ニッショー | 腹膜濾過装置 |
| JPH04308586A (ja) | 1991-04-05 | 1992-10-30 | Ono Pharmaceut Co Ltd | ベンゾピラン誘導体 |
| JPH05201993A (ja) | 1991-08-27 | 1993-08-10 | Otsuka Pharmaceut Co Ltd | メイラード反応阻害剤 |
| WO1993004690A1 (en) | 1991-09-09 | 1993-03-18 | Peptide Technology Limited | Method for the treatment of the complications and pathology of diabetes |
| JPH05105633A (ja) | 1991-10-14 | 1993-04-27 | Shimizu Seiyaku Kk | ブドウ糖製剤及びその製造方法 |
| US5246971A (en) | 1991-12-16 | 1993-09-21 | Washington University | Method of inhibiting nitric oxide formation |
| DE4204561A1 (de) | 1992-02-13 | 1993-08-19 | Falk Witt | Verfahren und einrichtung zur behandlung von gasen und fluessigkeiten |
| JPH05255130A (ja) | 1992-03-16 | 1993-10-05 | Asai Gerumaniumu Kenkyusho:Kk | メイラード反応抑制改善剤 |
| DE59206619D1 (de) * | 1992-04-06 | 1996-07-25 | Baxter Int | Wässrige Peritonealdialyse-Lösung |
| US5827820A (en) | 1992-04-06 | 1998-10-27 | Baxter International Inc. | Aqueous peritoneal dialysis solution |
| DE4222980A1 (de) | 1992-07-13 | 1994-01-20 | Cassella Ag | Verwendung von 2-(N-(2-Aminoethyl)amino)-essigsäure-derivaten |
| WO1994004520A1 (en) | 1992-08-11 | 1994-03-03 | Immuno Japan Inc. | Ascofuranone, and hypolipidemic agent, hypoglycemic agent and glycation inhibitor each containing ascofuranone derivative as active ingredient |
| JPH0816057B2 (ja) | 1992-09-10 | 1996-02-21 | 田村 學造 | グリケイション阻害剤 |
| JPH06135698A (ja) | 1992-10-23 | 1994-05-17 | Shinko Electric Co Ltd | フォークリフトの荷役制御装置 |
| JP3267698B2 (ja) | 1992-10-27 | 2002-03-18 | 株式会社三和化学研究所 | ヒダントイン誘導体及びその塩並びにこれらを有効成分とするメイラード反応阻害剤 |
| CA2103189C (en) | 1992-11-17 | 2005-05-03 | Lorne M. Golub | Tetracyclines including non-antimicrobial chemically-modified tetracyclines inhibit excessive collagen crosslinking during diabetes |
| JPH06192089A (ja) | 1992-12-25 | 1994-07-12 | Yamanouchi Pharmaceut Co Ltd | メイラード反応阻害剤 |
| JPH06298737A (ja) | 1993-04-13 | 1994-10-25 | Yamanouchi Pharmaceut Co Ltd | ピラゾール誘導体 |
| JPH06287180A (ja) | 1993-03-31 | 1994-10-11 | Yamanouchi Pharmaceut Co Ltd | アミジノインダゾール誘導体 |
| JPH06298738A (ja) | 1993-04-15 | 1994-10-25 | Yamanouchi Pharmaceut Co Ltd | ５−アミノピラゾール誘導体 |
| JPH06287179A (ja) | 1993-04-02 | 1994-10-11 | Yamanouchi Pharmaceut Co Ltd | ５−ヒドロキシピラゾリン誘導体 |
| US5677322A (en) | 1993-02-26 | 1997-10-14 | Otsuka Pharmaceutical Co., Ltd. | Maillard reaction inhibitor |
| JPH06305964A (ja) | 1993-02-26 | 1994-11-01 | Otsuka Pharmaceut Co Ltd | メイラード反応阻害剤 |
| JPH06305969A (ja) | 1993-04-27 | 1994-11-01 | Yoshitomi Pharmaceut Ind Ltd | 坐 剤 |
| PT963756E (pt) | 1993-12-21 | 2004-06-30 | Lilly Co Eli | Inibicao da oxidacao do ldl e da aterosclerose |
| JPH07206838A (ja) | 1994-01-14 | 1995-08-08 | Immuno Japan:Kk | 新規なアスコフラノン誘導体並びにそれらを有効成分とする血中脂質低下剤、血糖低下剤、グリケイション阻害剤及び抗酸化剤 |
| FR2716199B1 (fr) | 1994-02-15 | 1996-04-26 | Roquette Freres | Procédé de fabrication d'un hydrolysat d'amidon à faible indice de polymolécularité, nouvel hydrolysat d'amidon ainsi obtenu et son utilisation en dialyse péritonéale. |
| JPH07247296A (ja) | 1994-03-08 | 1995-09-26 | Asai Gerumaniumu Kenkyusho:Kk | 有機ゲルマニウム化合物 |
| JP3589701B2 (ja) | 1994-05-31 | 2004-11-17 | 味の素ファルマ株式会社 | トレハロース含有腹膜透析液 |
| SE9402472L (sv) | 1994-07-13 | 1996-01-14 | Forskarpatent I Linkoeping Ab | Modifierade ytor |
| JPH0859485A (ja) | 1994-08-26 | 1996-03-05 | Sanwa Kagaku Kenkyusho Co Ltd | ３ーオキシゲルミルプロピオン酸化合物を主成分とするメイラード反応阻害剤 |
| JPH0871146A (ja) | 1994-09-09 | 1996-03-19 | Baxter Kk | シクロデキストリン又はその誘導体を含有する腹膜透析液 |
| JPH08157473A (ja) | 1994-10-06 | 1996-06-18 | Nissan Chem Ind Ltd | ピラゾール系チアゾリジン類 |
| JP3644024B2 (ja) | 1994-11-04 | 2005-04-27 | 順子 清水 | 腹膜透析液 |
| JPH08131542A (ja) | 1994-11-11 | 1996-05-28 | Baxter Kk | 腹膜透析液調製用溶液セット |
| US5962245A (en) | 1995-04-05 | 1999-10-05 | The Picower Institute For Medical Research | Methods for detecting the presence of advanced glycosylation endproducts |
| AU5386996A (en) | 1995-04-05 | 1996-10-23 | Picower Institute For Medical Research, The | Agents for binding to advanced glycosylation endproducts, an d methods of their use |
| JPH0940519A (ja) | 1995-07-26 | 1997-02-10 | Nippon Flour Mills Co Ltd | メイラード反応抑制剤及び化粧料 |
| JPH0940626A (ja) | 1995-07-27 | 1997-02-10 | Kissei Pharmaceut Co Ltd | ビス（２−ヒドロキシフェニルアルキルアミン）誘導体 |
| JPH0959258A (ja) | 1995-08-11 | 1997-03-04 | Ono Pharmaceut Co Ltd | グアニジル誘導体 |
| JPH0959233A (ja) | 1995-08-25 | 1997-03-04 | Kissei Pharmaceut Co Ltd | ｏ−ヒドロキシナフチルアルキルアミン誘導体 |
| US5944684A (en) * | 1995-08-31 | 1999-08-31 | The Regents Of The University Of California | Wearable peritoneum-based system for continuous renal function replacement and other biomedical applications |
| US5744451A (en) | 1995-09-12 | 1998-04-28 | Warner-Lambert Company | N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity |
| JPH09124471A (ja) | 1995-10-30 | 1997-05-13 | Kissei Pharmaceut Co Ltd | メイラード反応阻害剤 |
| US6727285B1 (en) | 1995-11-07 | 2004-04-27 | George M. Haik, Jr. | Use of D-arginine and/or L-arginine to protect the amino groups of biological substances from damage, inactivation, or modification by toxic carbonyls and/or dicarbonyls |
| JP3147143B2 (ja) | 1995-11-10 | 2001-03-19 | 宇部興産株式会社 | 竪型粉砕機 |
| JPH09221427A (ja) | 1996-02-14 | 1997-08-26 | Mikio Ito | 痔疾患用剤 |
| JP3872834B2 (ja) | 1996-03-04 | 2007-01-24 | 第一製薬株式会社 | メイラード反応抑制剤 |
| JP3988838B2 (ja) | 1996-05-29 | 2007-10-10 | 日本製粉株式会社 | 化粧料 |
| JP3630857B2 (ja) | 1996-06-17 | 2005-03-23 | キヤノン株式会社 | 眼科撮影装置 |
| US5868936A (en) | 1996-06-20 | 1999-02-09 | Baxter International Inc. | Affinity membrane system and method of using same |
| JPH1094598A (ja) | 1996-07-31 | 1998-04-14 | Baxter Internatl Inc | 腹膜透析液 |
| JPH10158265A (ja) | 1996-11-29 | 1998-06-16 | Nippon Zoki Pharmaceut Co Ltd | ピロロナフチリジニウム誘導体 |
| JPH10158244A (ja) | 1996-12-02 | 1998-06-16 | Kissei Pharmaceut Co Ltd | ５−アミノアルキル−４−アミノメチル−３−ヒドロキシピリジン誘導体およびそれらを含有するメイラード反応阻害剤 |
| JPH10175954A (ja) | 1996-12-12 | 1998-06-30 | Kissei Pharmaceut Co Ltd | ４−アミノメチル−３−ヒドロキシピリジン誘導体およびそれらを含有するメイラード反応阻害剤 |
| JPH10182460A (ja) | 1996-12-27 | 1998-07-07 | Nippon Zoki Pharmaceut Co Ltd | ３−デオキシグルコソン生成阻害剤 |
| WO2000010606A1 (fr) | 1998-08-24 | 2000-03-02 | Kurokawa, Kiyoshi | Medicaments de sedation de l'agression du carbonyle et des dialysats peritoneaux |
| AU778462C (en) | 1999-05-12 | 2006-02-02 | Kurokawa, Kiyoshi | Blood carbonyl compound-trapping agent |
| AU780855B2 (en) | 1999-10-06 | 2005-04-21 | Kurokawa, Kiyoshi | Carbonyl stress-decreasing agent |
| EP1240902B1 (en) | 1999-12-20 | 2013-02-13 | Kurokawa, Kiyoshi | Carbonyl stress-ameliorating agents |
-
1999
- 1999-08-23 WO PCT/JP1999/004521 patent/WO2000010606A1/ja not_active Application Discontinuation
- 1999-08-23 CN CNB998125458A patent/CN1150034C/zh not_active Expired - Fee Related
- 1999-08-23 JP JP2000565926A patent/JP3811008B2/ja not_active Expired - Fee Related
- 1999-08-23 AU AU53045/99A patent/AU756847B2/en not_active Ceased
- 1999-08-23 CA CA2339879A patent/CA2339879C/en not_active Expired - Fee Related
- 1999-08-23 CA CA2664159A patent/CA2664159C/en not_active Expired - Fee Related
- 1999-08-23 EP EP09002868.9A patent/EP2070535B1/en not_active Expired - Lifetime
- 1999-08-23 EP EP99938581.8A patent/EP1108434B1/en not_active Expired - Lifetime
- 1999-08-23 KR KR10-2001-7002299A patent/KR100478181B1/ko not_active IP Right Cessation
- 1999-08-23 US US09/763,286 patent/US6919326B1/en not_active Expired - Fee Related
-
2001
- 2001-02-23 NO NO20010931A patent/NO329652B1/no not_active IP Right Cessation
-
2005
- 2005-03-29 US US11/093,950 patent/US7297689B2/en not_active Expired - Fee Related
-
2006
- 2006-09-22 US US11/534,375 patent/US7745613B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2339879A1 (en) | 2000-03-02 |
| CA2664159A1 (en) | 2000-03-02 |
| CA2339879C (en) | 2011-11-15 |
| US20070020341A1 (en) | 2007-01-25 |
| EP2070535A1 (en) | 2009-06-17 |
| AU756847B2 (en) | 2003-01-23 |
| AU5304599A (en) | 2000-03-14 |
| NO20010931D0 (no) | 2001-02-23 |
| US6919326B1 (en) | 2005-07-19 |
| EP1108434A4 (en) | 2008-03-26 |
| KR20010072888A (ko) | 2001-07-31 |
| CN1150034C (zh) | 2004-05-19 |
| US20050267045A1 (en) | 2005-12-01 |
| WO2000010606A1 (fr) | 2000-03-02 |
| CN1324248A (zh) | 2001-11-28 |
| KR100478181B1 (ko) | 2005-03-23 |
| US7745613B2 (en) | 2010-06-29 |
| JP3811008B2 (ja) | 2006-08-16 |
| CA2664159C (en) | 2013-06-04 |
| EP1108434B1 (en) | 2014-05-14 |
| NO20010931L (no) | 2001-04-23 |
| US7297689B2 (en) | 2007-11-20 |
| EP1108434A1 (en) | 2001-06-20 |
| EP2070535B1 (en) | 2015-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO329652B1 (no) | Anvendelse av aktivert trekull til fremstilling av et middel for inhibering av peritonealdialyseassosierte komplikasjoner, samt fremgangsmate for fremstilling av peritonealdialysevaeske med redusert karbonylforbindelsesinnhold. | |
| KR0145289B1 (ko) | 히스티딘 완충 복막 투석 용액 | |
| US6214802B1 (en) | Peritoneal dialysis fluid | |
| JP3262620B2 (ja) | 腹膜炎によって生ずる傷害および生理学的副作用を最小にするために使用し得る腹膜透析液 | |
| JP2011173904A (ja) | カルボニルストレス改善剤 | |
| US6241943B1 (en) | Use of a solution comprising glucose for peritoneal dialysis having reduced formation of age products | |
| Ho-Dac-Pannekeet et al. | Analysis of non enzymatic glycosylation in vivo: impact of different dialysis solutions | |
| JP2006305345A (ja) | カルボニルストレス状態改善剤、および腹膜透析液 | |
| JP4061775B2 (ja) | アルブミン含有腹膜透析液 | |
| Krishnan et al. | Glucose degradation products (GDP’s) and peritoneal changes in patients on chronic peritoneal dialysis: will new dialysis solutions prevent these changes? | |
| Pischetsrieder et al. | Chemistry and clinical relevance of carbohydrate degradation in drugs | |
| US7169407B1 (en) | Carbonyl stress-decreasing agent | |
| JP4526192B2 (ja) | 血中カルボニル化合物トラップ剤 | |
| US20040229771A1 (en) | Method of reducing decline of or preserving residual renal function | |
| Coles | Biocompatibility of various osmotic solutes | |
| WO2009117302A1 (en) | Removal of substances in dialysis solutions and dialysis components by ion exchange adsorption | |
| Rippe et al. | Long-term results with low glucose degradation product content in peritoneal dialysis fluids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |